Navigation Links
Caris Life Sciences Collaborates with GenoSpace to Enhance Data Mining Capabilities to Advance the Molecular Understanding of Cancer
Date:8/14/2014

IRVING, Texas, Aug. 14, 2014 /PRNewswire/ -- Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, today announced a collaboration with GenoSpace, a Massachusetts-based technology company that develops robust software solutions for genomic and health data.  Caris will apply GenoSpace's population analytics offerings to uncover and better utilize key insights from the company's industry-leading tumor profiling service, Caris Molecular Intelligence™. The partnership also leverages GenoSpace's analytics architecture expertise to unlock key treatment insights from the Caris Registry™, a database of clinicopathologic and outcome variables from consenting patients whose tumors underwent multi-technology profiling by Caris.

"This collaboration demonstrates our commitment to advancing and improving cancer care through intelligent, targeted and patient-centric research," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "Building on our industry-leading informatics capabilities, our partnership with a company like GenoSpace further establishes our leadership position in providing the highest quality and most clinically actionable tumor profiling information available to physicians and patients today."

With more than 65,000 patients profiled to date, Caris is uniquely positioned to leverage its institutional knowledge and expertise to offer enhanced analysis of its vast tumor profiling databases, in accordance with applicable federal and state laws governing privacy and secondary research.  Caris' tumor profiling databases are comprised of multiple assay technologies performed in combination to achieve the most comprehensive molecular profile of a tumor. The resulting analysis and insights, enabled in part by this collaboration, will create a HIPAA-compliant informatics platform that provides Caris' institutional partners the ability to investigate institution-specific profiling data within Caris Molecular Intelligence, expanding and enriching their own research goals. It also allows Caris to more efficiently and expediently isolate novel and/or critical drug-biomarker associations, ultimately providing better treatment information to oncologists and their patients.

"Our collaboration with Caris Life Sciences illustrates our shared passion and commitment to providing precise, actionable information to physicians, their patients and the cancer research community," said John Quackenbush, PhD, CEO of GenoSpace. "The combination of GenoSpace's population analytics offerings and Caris' unprecedented database and registry will provide a unique opportunity for discovery of new biomarkers that can predict a wide range of clinically relevant endpoints and ultimately lead to improvements in the quality and cost of patient care."

About Caris Life Sciences

Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalized medicine.  As the first commercial mover in comprehensive molecular profiling in oncology, Caris Molecular Intelligence™ is an industry vanguard, with 65,000-plus patients profiled and counting. Ordered by nearly 7,000 oncologists in 63 countries, Molecular Intelligence correlates molecular data generated from a patient's tumor with biomarker/drug associations derived from clinical cancer literature. Using a variety of advanced and clinically-relevant technologies, Caris provides oncologists with the most clinically actionable information to help them personalize treatment for cancer patients. This multi-technology approach enables Caris to provide therapeutic guidance for 55 drug associations, compared to the 19 that can be found through use of next-generation sequencing alone. The company is also developing a series of blood tests based on its proprietary Carisome® platform — a revolutionary blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.carislifesciences.com.

About GenoSpace

At GenoSpace, we are Digital Architects of Genomic Medicine™. GenoSpace is a Cambridge, Massachusetts-based precision medicine software company that has developed a comprehensive suite of offerings for securely storing vast amounts of genomic and health data, and providing it in formats specific to its diverse user communities. GenoSpace for Clinical™ and GenoSpace for Labs™ facilitate clinically actionable interpretation and report generation for precision medicine. GenoSpace for Research™ provides dynamic analysis, visualization and collaboration tools on an advanced population analytics platform. GenoSpace for Patient Communities™ enables patient-centric exploration and advancement of personalized medicine. Please visit www.genospace.com for more information.


'/>"/>
SOURCE Caris Life Sciences
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Caris Life Sciences Receives Tumor Profiling Industrys First ISO 15189 Medical Laboratory Accreditation
2. The Caristix HL7 Survival Guide: Understand the Complete Interface Lifecycle
3. Dr. Joachim Schorr (PhD) zum Chief Scientific Officer von Caris Life Sciences bestellt
4. Joachim Schorr, PhD, Named Chief Scientific Officer at Caris Life Sciences
5. Kindred Biosciences Announces Second Quarter 2014 Financial Results
6. Pressure BioSciences, Inc. to Discuss Second Quarter 2014 Financial Results and Provide a Business Update
7. Ambit Biosciences Announces Second Quarter 2014 Operating Results
8. Protein Sciences and Liomont Announce Licensing of Proprietary Influenza Vaccines for the Mexico Market
9. Christopher Church joins Kineticos Life Sciences as Managing Director
10. BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission on Track following Pre-NDA Meeting with FDA
11. Lexicon To Present At The 2014 Wedbush Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Spiral Therapeutics, Inc. today ... Bionure Farma, S.L. for the worldwide exclusive rights ... in the field of otolaryngology for aggregate payments ... The agreement provides Spiral with the option ... differentiated product profile. Under the terms of the ...
(Date:3/29/2017)... , March 29, 2017   Royal ... leader in health technology, and PathAI, a company ... collaborating with the aim to develop solutions that ... of cancer and other diseases. The partnership aims ... enabling this form of artificial intelligence to be ...
(Date:3/29/2017)... , USA, March 29, 2017 Stryker ... that Cares by People magazine, in partnership with Great ... 50 companies on the list. This list highlights the ... have succeeded in business while also demonstrating respect, compassion ... environment.  To determine the companies on ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash ... has enlisted New York City-based sports and entertainment marketing firm Leverage Agency as ... opportunities for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its ... from high school and college students who have participated in the program every summer. ... YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold ... in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results ... in HeartBoost, an over the counter heart healthy drink, can reduce Arterial Plaque, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general ... accepting new pediatric patients, with or without a referral. Dr. Cotey knows that ... orthodontic outcome and experience. When patients receive early treatment, they may achieve straight teeth ...
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
Breaking Medicine News(10 mins):